A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

Rheumatoid Arthritis Clinical Trial

— RI-01-007  

Official title:

A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04268771
• Other study ID #: RI-01-007
• Status: Completed
• Phase: Phase 3
• Start date: April 8, 2020
• Est. completion date: April 20, 2022

Study information

• Verified date: October 2023
• Source: Dr. Reddy's Laboratories Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the current study is to assess the immunogenicity and safety of transitioning subjects with RA to DRL_RI from US-rituximab/EU-rituximab to continued treatment with US-rituximab/EU-rituximab. The primary objective of this study is to assess the immunogenicity of transitioning subjects with RA to DRL_RI (biosimilar rituximab) from US-rituximab/EU-rituximab to continued treatment with US-rituximab/EU-rituximab To assess the safety of transitioning subjects with RA to DRL_RI from US-rituximab/EU-rituximab to continued treatment with US-rituximab/EU-rituximab.

Description:

This is a randomized, double-blind, parallel group, multicenter, Phase 3 transition study in subjects with active RA who are eligible for the subsequent treatment course with US-rituximab or EU-rituximab according to the clinical judgment of the investigator. Subjects will then be randomized by interactive web response system (IWRS) to receive either two 1000 mg infusions of DRL_RI (Arm A) or US-rituximab/EU-rituximab (Arm B) on Day 1 and Day 15. Subjects randomized to Arm A will receive DRL_RI and subjects randomized to Arm B will continue to receive either US-rituximab or EU-rituximab. The study will consist of a screening period (Days -14 to 0) and a double-blind period (Day 1 to Week 12). Subjects will attend a screening visit followed by a visit at Weeks 0 (Day 1), 2, 4, 8, and 12 after randomization It is planned that approximately 50 sites will be initiated for this study in up to 7 countries (including but not restricted to United States). There has been no randomization of patients till date for this study. The study endpoints include: The immunogenicity endpoint is: • The incidence of anti-drug antibodies (ADA), including titer and neutralizing antibodies (NAb). The primary safety endpoints are: - Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). - Incidence of anaphylactic reactions, hypersensitivity reactions, and IRRs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: April 20, 2022
• Est. primary completion date: January 26, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female subjects aged 18 years or older who have provided valid written informed consent.

2. Subjects with a diagnosis of active RA who are eligible for the subsequent treatment course with US-rituximab or EU-rituximab according to the clinical judgment of the investigator.

3. Documented evidence that subject has received at least 1 full course comprising two 1000 mg infusions of either US-rituximab at least 16 weeks prior to the randomization visit or EU-rituximab at least 24 weeks prior to the day of randomization visit.

4. Subjects receiving a stable dose of weekly methotrexate (MTX) for at least 4 weeks prior to randomization (between 7.5 mg and 25 mg) and folic acid (at least 5 mg per week. EXCLUSION CRITERIA;

1. Subjects with RA in functional Class IV

2. Subjects with human immunodeficiency virus (positive HIV1Ab or HIV2Ab), hepatitis B virus and/or hepatitis C virus infection, including those with positive results in the viral disease screening.

3. Subjects with active tuberculosis. Subjects with evidence of latent TB or a history of TB must have completed treatment or have initiated treatment for at least 1 month before the first dose of study treatment (Day 1). TB testing is required only if it is required by local regulations or practice.

4. Active systemic infection.

5. Severely immunocompromised.

6. History of severe hypersensitivity to either US-rituximab or EU-rituximab or any of its excipients requiring drug discontinuation.

7. Any serious illness or uncontrolled medical condition, including but not limited to severe infections, significant hepatic or renal disease, uncontrolled hypertension despite treatment (defined as blood pressure =160/95 mmHg), congestive heart failure (New York Heart Association [NYHA] Class III or IV), or other severe, uncontrolled cardiac disease or uncontrolled diabetes with immediate risk of acute complications.

8. Any condition that in the opinion of the investigator represents an obstacle for study conduct and/or represents a potential unacceptable risk for subjects.

9. Requires treatment with any biological medicinal product during the study other than the study treatment.

10. Previous treatment with B-cell modulating or cell depleting biologic therapy except US-rituximab or EU-rituximab.

11. Prior participation in this clinical trial or prior participation in any clinical trial with any monoclonal antibody within 12 months of screening or prior participation in any clinical trial within 3 months of screening or within 5 half-lives of the investigational drug or until the expected PD effect has returned to baseline, whichever is longer.

12. Treatment with other biologic disease-modifying anti-rheumatic drugs, or Janus kinase (JAK) inhibitors administered within 12 weeks before the first dose of rituximab of the prior treatment course onwards till the date of randomization.

13. Subjects with the following laboratory abnormalities:

• Subjects with screening total white blood cell count <3000/µL, platelets <100,000/µL, neutrophils <1,500/µL, or hemoglobin <8.5 g/dL
• Abnormal liver function tests such as aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase >2 × upper limit of normal (ULN). A single parameter >2 × ULN can be re-checked as soon as possible, at least prior to randomization, if required as per the investigator's discretion.
• Creatinine clearance (Cockcroft & Gault formula) of less than 50 mL/min.

14. History of vaccination with live vaccines within 4 weeks of the first dose of study treatment (Day 1) or known to require live vaccines during the study.

15. Lactating or pregnant female.

16. Women of childbearing potential who do not consent to use highly effective methods of birth control (e.g., barrier contraceptives, oral contraceptives, intrauterine devices, true abstinence if it allowed as per the country specific regulatory requirement [periodic abstinence {e.g., calendar ovulation, symptothermal, post-ovulation methods} and withdrawal are not acceptable methods of contraception], or sterilization) during treatment and for at least 12 months after the last administration of study treatment.

17. For men involved in any sexual intercourse that could lead to pregnancy, subjects must agree to use 1 of the highly effective methods of birth control listed in Exclusion Criterion #16 during treatment and for at least 12 months after the last administration of study treatment.

18. Subject with serum IgG < lower limit of normal.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Biological:
• Experimental: Arm A: DRL_RI
Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion
• Arm B: Rituxan®/Mabthera®
Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion

Locations

Country	Name	City	State
United States	MedBio Trials	Aventura	Florida
United States	Accurate Clinical Management, LLC	Baytown	Texas
United States	Trinity Clinical Research LLC, 2008 East Hebron Parkway, Suites 120/114/100,	Carrollton	Texas
United States	Integrative Rheumatology	Charlotte	North Carolina
United States	Clinical Research of West Florida Inc - Clearwater	Clearwater	Florida
United States	Altoona Center For Clinical Research, 175 Meadowbrook Lane,	Duncansville	Pennsylvania
United States	Arthritis and Osteoporosis Associates	Freehold	New Jersey
United States	Abigail Neiman	Houston	Texas
United States	Accurate Clinical Management, LLC	Houston	Texas
United States	Accurate Clinical Research-Houston, 11003 Resource Parkway, Suite 102	Houston	Texas
United States	Laila A Hassan, MD, PA	Houston	Texas
United States	Houston Rheumatology & Arthritis Specialists	Katy	Texas
United States	Rheumatology Consultant of Delaware dba Delaware Arthritis	Lewes	Delaware
United States	Bluegrass Community Research Inc,330 Waller Avenue, Suite 100,	Lexington	Kentucky
United States	AppleMed Research Group, LLC	Miami	Florida
United States	Medical Research Center	Miami	Florida
United States	California Allergy and Asthma Medical Group - CRN - PPDS 41230 11th Street West, Suite A	Palmdale	California
United States	Arizona Arthritis and Rheumatology Research, PLLC	Phoenix	Arizona
United States	Integral Rheumatology and Immunology Specialist, 140 Southwest 84th Avenue, Suite B	Plantation	Florida
United States	Accurate Clinical Research, Inc.	San Antonio	Texas
United States	Clinical Associates in Research Therapeutics of America, LLC	San Antonio	Texas
United States	Springfield Clinic (Clinic location)	Springfield	Illinois
United States	Articularis Healthcare Group, Inc dba Low Country Rheumatology	Summerville	South Carolina
United States	Vicis Clinical Research INC	Tampa	Florida
United States	Accurate Clinical Research-League City	Texas City	Texas
United States	Inland Rheumatology Clinical Trials Incorporated	Upland	California

Sponsors (2)

Lead Sponsor	Collaborator
Dr. Reddy's Laboratories Limited	PPD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Positive Anti-Drug Antibodies (ADA) on Day 1	For Immunogenicity: Number of subjects with positive Anti-Drug Antibodies (ADA) on Day 1 was reported	ADA will be obtained before the administration of study treatment on Day 1
Primary	Number of Subjects With Positive Anti-Drug Antibodies (ADA) on Day 15	For Immunogenicity: Number of subjects with positive Anti-Drug Antibodies (ADA) on Day 15 was reported	ADA will be obtained before the administration of study treatment on Day 15
Primary	Number of Subjects With Positive Anti-Drug Antibodies (ADA) at Week 4	For Immunogenicity: Number of subjects with positive Anti-Drug Antibodies (ADA) at Week 4 was reported	ADA will be obtained before the administration of study treatment at Week 4
Primary	Number of Subjects With Positive Anti-Drug Antibodies (ADA) at Week 8	For Immunogenicity: Number of subjects with positive Anti-Drug Antibodies (ADA) at Week 8 was reported	ADA will be obtained before the administration of study treatment at Week 8
Primary	Number of Subjects With Positive Anti-Drug Antibodies (ADA) at Week 12 Visits	For Immunogenicity: Number of subjects with positive Anti-Drug Antibodies (ADA) at Week 12 visits was reported	ADA will be obtained at Week 12
Secondary	Number of Subjects Reporting Anaphylactic Reactions at Dosing Time Points (Either at Week 1 or Week 3)	Number of Subjects reporting anaphylactic reactions during the study drug administration either at Week 1 or Week 3 was reported	Assessments of Anaphylactic reactions will be carried out at either Week 1 or Week 3
Secondary	Number of Subjects Reporting TEAEs (Treatment Emergent Adverse Events) That Led to Study Drug Discontinuation at Either Week 1 or Week 3 Dosing Timepoint	TEAEs (Treatment emergent adverse events) which lead to study subjects discontinuation from the study drug administration at either week 1 or week 3 dosing timepoint	Assessment of AE's (Adverse Events) that led to study drug discontinuation were carried out at either week 1 or week 3 dosing timepoint
Secondary	Number of Subjects Reporting SAEs (Serious Adverse Events) From Baseline (Week 1) to End of Study (Week 26)	Incidence of SAEs: SAE is defined as "Results in death, is life-threatening, Requires in-subject hospitalization or prolongs existing hospitalization, Results in persistent or significant disability/incapacity".; The measure here is only subjects reporting SAE.	Assessment of SAE's was carried out from baseline (week 1) to end of study (week 26)
Secondary	Number of TEAEs Reported From Baseline (Week 1) to End of Study (Week 26)	Number of TEAEs: Treatment-emergent AE are defined as any AE occurring or worsening on or after the first dose of study medication.	Assessment of AE's will be carried out from baseline (week 1) to end of study (week 26)
Secondary	Number of Subjects Reporting AE From Baseline (Week 1) to End of Study (Week 26)	number of subjects reporting AE in the overall study are defined as any AE occurring or worsening after the ICF signed in the study	Assessment of AE's will be carried out from baseline (week 1) to end of study (week 26)
Secondary	Number of Subjects Reporting TEAEs From Baseline (Week 1) to End of Study (Week 26)	Number of subjects reporting Treatment-emergent AE (TEAEs) are defined as any AE occurring or worsening on or after the first dose of study medication.	Assessment of AE's will be carried out from baseline (week 1) to end of study (week 26)
Secondary	Number of Subjects Reporting Hypersensitivity Reactions at Dosing Time Points (Either at Week 1 or Week 3)	Safety assessment will be done by measuring hypersensitivity reactions at Dosing Time Points (Either at Week 1 or Week 3)	Assessments of hypersensitivity reactions either at Week 1 or Week 3
Secondary	Number of Subjects Reporting Infusion-related Reactions (IRRs) at Dosing Time Points (Either at Week 1 or Week 3)	Safety assessment: Number of Subjects Reporting Infusion-related reactions (IRRs) at Dosing Time Points (Either at Week 1 or Week 3) was reported	Assessments of IRRs were carried out at either Week 1 or Week 3